European Watchdog Partially Approves New Alzheimer's Drug
Mohammad Ali (@ChaudhryMAli88) Published November 15, 2024 | 01:10 AM
Amsterdam, (APP - UrduPoint / Pakistan Point News - 15th Nov, 2024) Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.
"After re-examining its initial opinion, the EMA... has recommended granting marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to Alzheimer's disease," the European Medicines Agency said, adding treatment would only apply to a certain group of patients.
Leqembi, which was developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.
The EMA in July rejected a marketing request by the companies, saying the side effects, including potential brain bleeding, outweighed the benefits.
The EMA now endorsed the treatment, but only for patients with a lower risk of potential brain bleeding -- those who had "only one copy or no copy of ApoE4," a type of gene know as an important risk factor for Alzheimer's.
Such patients are less likely to experience certain serious health problems than people with two copies of the gene, the Amsterdam-based EMA said.
The health problems in question, known as amyloid-related imaging abnormalities (ARIA), include fluid on the brain and brain bleeding.
"The benefits of Leqembi outweigh the risks in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease with one or no copy of ApoE4."
This was "provided that risk minimisation measures are in place to reduce the risk of severe and symptomatic ARIA and monitor its consequences in the long term," it stressed.
Bringing down the risks included providing Leqembi through a "controlled access programme to ensure that the medicine is only used in the recommended patient population" and through MRI scans before and during treatment.
Recent Stories
Currency Rate In Pakistan - Dollar, Euro, Pound, Riyal Rates On 6 December 2024
Today Gold Rate in Pakistan 06 December 2024
50 shops sealed over anti-smog SOPs violations in 24 hours
IFJ holds workshop to enhance journalist safety & gender equality in media
Many Balochistan educationists on govt-sponsored scholarships fail to return
APC vows to safeguard rights of KP; demands performance audit of PTI Govt
RPO for improving security measures in Faisalabad
RPO visits Safe City Project, reviews technology installation
Deputy Commissioner (DC) Lahore Syed Musa Raza active in field for 'Lahore Clean ..
Commissioner Lahore Zaid Bin Masood reviews schemes under Lahore development pla ..
Dacoits loot cash, gold worth Rs 5.8m from landlord's family
Azad Jammu and Kashmir (AJK) President Barrister Sultan Mahmood Chaudhrypays tri ..
More Stories From World
-
Bellingham back to best as Real Madrid face Girona
9 minutes ago -
Fresh protests in Georgia after PM vows to 'eradicate' opposition
9 minutes ago -
Blinken tells counterpart confident in S. Korean democracy
10 minutes ago -
'People want change': inside Romania's far-right stronghold
10 minutes ago -
Harrison Ford gets de-aged again for 'Indiana Jones' video game
19 minutes ago -
Copenhagen takes on its biggest climate threat -- water
19 minutes ago
-
Musk heads to US Congress to discuss slashing government costs
19 minutes ago -
Artists abandon Abidjan for Ivory Coast beachside haven
20 minutes ago -
South Korean ruling party says 'dangerous' president must go
30 minutes ago -
US neighbors balk at Trump plan for deported migrants
59 minutes ago -
EU chief in last-gasp push to close South America trade deal
1 hour ago -
UN slams Taliban ban on women from pursuing medical education; top Afghan cricketers seek reversal
1 hour ago